0001558370-25-011776
SEC filingRisk factors emphasize regulatory threats to key antibacterials, geopolitical exposure in Israel and Brazil, and risks from animal disease outbreaks.
Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company. The company strives to be a trusted partner with livestock producers, farmers, veterinarians and consumers by providing solutions to maintain and enhance animal health. It markets approximately 800 product lines in approximately 90 countries to approximately 4,500 customers. Its products include animal health products such as antibacterials, anticoccidials, nutritional specialty products, and vaccines, as well as mineral nutrition products that fortify the animal's diet.
The company manages its business in three reporting segments: Animal Health, Mineral Nutrition, and Performance Products. For the fiscal year ended June 30, 2025, net sales were $1,296 million, with Animal Health contributing 74% ($963 million), Mineral Nutrition 20% ($253 million), and Performance Products 6% ($80 million). The Animal Health segment develops, manufactures and markets about 340 product lines including MFAs and other, nutritional specialties, and vaccines. Mineral Nutrition manufactures and markets approximately 380 formulations of trace minerals. Performance Products manufactures and markets specialty ingredients for personal care, industrial chemical, and chemical catalyst industries.
Key products include antibacterials (Stafac, Terramycin, Mecadox, Aureomycin, LincoSpectin, BMD), anticoccidials (Nicarb, Coxistac, Aviax, Avatec, Bovatec, Cygro), nutritional specialties (OmniGen, Animate, Magni-Phi, MicroLife Prime, Cellerate Yeast Solutions), and vaccines (TAbic, MB-1, Tailor-Made, Phi-Shield). The company also has a companion animal product Rejensa joint care supplement for dogs. The acquisition of Zoetis's medicated feed additive portfolio in October 2024 added products such as Aureomycin, LincoSpectin, BMD, Avatec, Bovatec, Cygro, and others.
The company sells through a combination of direct sales representatives and third-party distributors. The Animal Health and Mineral Nutrition businesses have a sales, marketing and technical support organization of more than 520 employees and approximately 370 distributors. Products are sold directly to integrated livestock producers, feed manufacturers, wholesalers, and veterinarians. Performance Products are sold directly to customers in their respective industries. The company does not consider itself dependent on any single customer; the loss of any one would not have a material adverse effect.
The company operates in highly competitive industries. Competitors include global and regional firms with greater financial, R&D, manufacturing, and marketing resources. Competitive advantages are derived from product registrations, customer service, breadth of product line, product quality, manufacturing technology, and pricing. The company believes its leading positions in MFAs and nutritional specialties, global infrastructure, and diversified portfolio provide sustainable competitive advantages.
Key strategic pillars include focusing on regions with consolidated livestock production, investing in the companion animal segment, innovating in vaccine technologies (such as the TAbic effervescent tablet delivery platform), leveraging global presence in high-growth markets, and maintaining a diversified product portfolio across species and categories. The company also emphasizes cross-selling opportunities between Animal Health and Mineral Nutrition.
As of June 30, 2025, the company employed approximately 2,475 people across 70 locations in 36 countries. The company emphasizes talent development, safety (Road to Zero initiative), and a culture of diversity and inclusion. It uses the Denison Organization Culture survey to measure organizational health.
The most material risk is the potential FDA withdrawal of the Mecadox (carbadox) product, which generated ~$20 million in fiscal 2025 sales. The company is contesting the FDA's actions through litigation and a requested evidentiary hearing. Broader regulatory trends, including FDA Guidance 273, threaten to shorten the approved duration of use for medically important antimicrobials, which constitute a large portion of the Animal Health segment's $646 million antibacterial sales (50% of total net sales in FY2025). Geopolitical exposure is significant: 16% of assets are in Israel, subject to the ongoing conflict with Hamas and potential broader regional war. Brazil accounts for 10% of assets, with currency and political instability risks. The company also notes risks from trade protectionism and sanctions affecting customers and supply chains.
Animal disease outbreaks (e.g., African Swine Fever, Highly Pathogenic Avian Influenza) pose recurring demand risks; recent H5N1 outbreaks led to culling of over 131 million poultry. Climate change could exacerbate these through heat stress, drought, and disease patterns. The company depends on a few manufacturing sites, with several product lines produced at single facilities, increasing disruption risk. Raw material costs are volatile, though no single material exceeds 5% of COGS.
High debt (approximately $725 million drawn under the 2024 Credit Facilities) requires steady cash flow for servicing. The acquisition of Zoetis's MFA portfolio for ~$297.5 million adds integration risk. Competition from generics is intensifying, and customer consolidation increases pricing pressure. The company's concentrated voting control (90.9% held by BFI) limits minority shareholder influence and introduces related-party risks.
Cybersecurity incidents have occurred but not been material; however, increasing IT reliance and AI adoption introduce new vulnerabilities. Failure to maintain effective internal controls over financial reporting could lead to material misstatements. The company also faces product liability, intellectual property, and environmental liability risks, though these are considered ordinary course.